Recognising the importance of plasma and with over 60 years of experience in the industry, BPL supplies high-quality plasma-derived medicines to meet the needs of clinicians, patients and customers globally.
Headquartered in Elstree, in the UK, and with plasma collection centres across the US, BPL is dedicated to producing a range of medicines for the treatment of immune deficiencies, bleeding disorders and infectious diseases as well for critical care.
BPL’s plasma-derived medicines are commercially available in more than 50 countries worldwide through its network of local affiliates and distribution partners.
Our purpose is to enhance the lives of patients every day and support healthcare professionals by providing high-quality plasma-derived therapies worldwide.
What We Do
We are a trusted leader, an innovator and partner of choice in the processing of human plasma – collecting, developing, producing and commercialising a variety of plasma therapies worldwide.
BPL consists of two operating divisions, BPL Therapeutics (consisting of BPL Therapeutics in the UK and BPL Therapeutics US), and BPL Plasma.
BPL Therapeutics, headquartered in Elstree, UK, receives plasma that is collected in the US. This plasma is fractionated, purified and filled through the efforts of over 1,000 employees involved in production, quality, R&D, commercial, customer services and administrative activities. BPL’s operations are regulated by the MHRA and the DHSC in the UK.
BPL Therapeutics US, based in Durham, North Carolina, runs the Group’s global commercial operations. BPL Therapeutics US has close to 40 employees.
BPL Plasma, headquartered in Austin, Texas and operating in the US, collects plasma from donors, in 28 centres across the US. BPL Plasma employs close to 1000 staff, to support the needs of donors and to ensure high-quality plasma collection in all their centres. BPL Plasma operates clean and safe plasma facilities, staffed with trained personnel, dedicated to supporting donors through the process that leads to the donation of plasma. Plasma collection is regulated by both the FDA and the MHRA, and BPL follows industry guidelines.
Investment: We are focused on the development of our people, processes, research and technology. We invest in the latest R&D, technology and manufacturing methods, continuously adapting to ensure that we continue to serve all our stakeholders effectively.
Innovation: We apply innovative solutions today while investing in R&D to support our expansion. Our R&D structure is built to encourage innovation in new and existing products, indications and markets. We are building a patient-focused, clinically differentiated, global portfolio of rare disease therapies targeting unmet medical needs.
Global Expansion: We have worldwide expertise in multiple, growing markets, facilitating our commercial aims to address new market opportunities.
Entrepreneurial Spirit: We operate with a fresh, innovative approach so we can develop the right solution for each partner. We are the right size to meet customer needs – big enough to deliver, small enough to move with agility.
As the only plasma fractionator in the UK, we are proud to play a critical role in the UK life sciences industry and contribute to the growing global plasma products market in which we operate.